Neuromodulation for overactive bladder

Nature Reviews Urology

Volumn 10, Issue 9, 2013, Pages 513-521

  Bartley, Jamie ^a   Gilleran, Jason ^a   Peters, Kenneth ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BOTULINUM TOXIN A; CAFFEINE; DARIFENACIN; FESOTERODINE; MIRABEGRON; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLADDER TRAINING; CARBONATED BEVERAGE; CONSERVATIVE TREATMENT; CYSTOSCOPY; DRUG INDUCED HEADACHE; ECHOGRAPHY; ELECTROSTIMULATION; HUMAN; HYPERTENSION; INCONTINENCE; LONG TERM CARE; NERVE STIMULATION; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERACTIVE BLADDER; PATIENT SATISFACTION; PATIENT SELECTION; PELVIS FLOOR; PERCUTANEOUS NERVE EVALUATION; PHYSIOTHERAPY; POSTERIOR TIBIAL NERVE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PUDENDAL NERVE; REVIEW; RHINOPHARYNGITIS; SACRAL NERVE STIMULATION; SURGICAL TECHNIQUE; TIBIAL NERVE; URINARY DIVERSION; URINARY FREQUENCY; URINARY TRACT INFECTION; URODYNAMICS; XEROSTOMIA;

ELECTRIC STIMULATION THERAPY; HUMANS; NEUROTRANSMITTER AGENTS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 84883741571     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.143     Document Type: Review

References (85)

1. Abrams, P. et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol. Urodyn. 29, 213-240 (2010).
2. Haylen, B. T. et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int. Urogynecol. J. 21, 5-26 (2010).
3. Stewart, W. F. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20, 327-336 (2003).
4. Irwin, D. E. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur. Urol. 50, 1306-1314 (2006).
5. Milsom, I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760-766 (2001).
6. Coyne, K. S. et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77, 1081-1087 (2011).
7. Irwin, D. E., Kopp, Z. S., Agatep, B., Milsom, I. & Abrams, P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 108, 1132-1138 (2011).
8. Irwin, D. E. et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 103, 202-209 (2009).
9. Sexton, C. C. et al. Impact of overactive bladder on work productivity in the United States: Results from EpiLUTS. Am. J. Manag. Care 15, S98-S107 (2009).
10. Coyne, K. S. et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int. 101, 1388-1395 (2008).
11. Coyne, K. S., Margolis, M. K., Kopp, Z. S. & Kaplan, S. A. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology 79, 95-101 (2012).
12. Liu, R. T. et al. Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. Urology 78, 1040-1045 (2011).
13. Link, C. L., Steers, W. D., Kusek, J. W. & McKinlay, J. B. The association of adiposity and overactive bladder appears to differ by gender: Results from the Boston Area Community Health survey. J. Urol. 185, 955-963 (2011).
14. Wood, K. L., Folkerts, D., Finstrom, K. & Newman, C. Overactive bladder and urinary incontinence: A multitherapy approach to treatment. Sex. Reprod. Menopause 4, 66-70 (2006).
15. Klutke, C. G. et al. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J. Urol. 181, 2599-2607 (2009).
16. Stav, K. & Dwyer, P. L. Urinary bladder stones in women. Obstet. Gynecol. Surv. 67, 715-725 (2012).
17. Hanno, P. M. et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J. Urol. 185, 2162-2170 (2011).
18. Peters, K. M. & Carrico, D. J. Frequency, urgency, and pelvic pain: Treating the pelvic floor versus the epithelium. Curr. Urol. Rep. 7, 450-455 (2006).
19. Gormley, E. A. et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J. Urol. 188 (Suppl. 6), 2455-2463 (2012).
20. Dallosso, H. M., McGrother, C. W., Matthews, R. J. & Donaldson, M. M. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: A longitudinal study in women. BJU Int. 92, 69-77 (2003).
21. Lee, J. G., Wein., A. J. & Levin, R. M. The effect of caffeine on the contractile response of the rabbit urinary bladder to field stimulation. Gen. Pharmacol. 24, 1007-1011 (1993).
22. Burgio, K. L. Influence of behavior modification on overactive bladder. Urology 60, 72-76 (2002).
23. Godec, C. J. "Timed voiding"-a useful tool in the treatment of urinary incontinence. Urology 23, 97-100 (1984).
24. Burgio, K. L. et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA 288, 2293-2299 (2002).
25. Smith, A. L. & Wein, A. J. Recent advances in the development of antimuscarinic agents for overactive bladder. Trends Pharmacol. Sci. 31, 470-475 (2010).
26. Madhuvrata, P., Cody, J. D., Ellis, G., Herbison, G. P. & Hay-Smith, E. J. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst. Rev. 1, CD005429 (2012).
27. Chapple, C. R. et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur. Urol. 63, 296-305 (2012).
28. Nitti, V. et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J. Urol. 189, 1388-1395 (2012).
29. Yu, Y. F., Nichol, M. B., Yu, A. P. & Ahn, J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 8, 495-505 (2005).
30. Dmochowski, R. R. & Newman, D. K. Impact of overactive bladder on women in the United States: Results of a national survey. Curr. Med. Res. Opin. 23, 65-76 (2007).
31. Benner, J. S. et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 105, 1276-1282 (2010).
32. Wagg, A., Compion, G., Fahey, A. & Siddiqui, E. Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience. BJU Int. 110, 1767-1774 (2012).
33. Leng, W. W. & Chancellor, M. B. How sacral nerve stimulation neuromodulation works. Urol. Clin. North Am. 32, 11-18 (2005).
34. Langley, J. N. & Anderdon, H, K. The innervations of the pelvic and adjoining viscera. II. The bladder. J. Physiol. 19, 71-84 (1895).
35. Hald, T., Agrawal, G. & Kantrowitz, A. Studies in stimulation of the bladder and its motor nerves. Surgery 60, 848-856 (1966).
36. Heine, J. P., Schmidt, R. A. & Tanagho, E. A. Intraspinal sacral root stimulation for controlled micturition. Invest. Urol. 15, 78-82 (1977).
37. Brindley, G. S. Emptying the bladder by stimulating sacral ventral roots. J. Physiol. 237, 15P-16P (1974).
38. Tanagho, E. A. & Schmidt, R. A. Bladder pacemaker: Scientific basis and clinical future. Urology 20, 614-619 (1982).
39. Juenemann, K. P., Lue, T. F., Schmidt, R. A. & Tanagho, E. A. Clinical significance of sacral and pudendal nerve anatomy. J. Urol. 139, 74-80 (1988).
40. Tanagho, E. A. & Schmidt, R. A. Electrical stimulation in the clinical management of the neurogenic bladder. J. Urol. 140, 1331-1339 (1988).
41. South, M. M., Romero, A. A., Jamison, M. G., Webster, G. D. & Amundsen, C. L. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int. Urogynecol. J. Pelvic Floor Dysfunct. 18, 1395-1398 (2007).
42. Groenendijk, P. M. et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 101, 325-329 (2008).
43. Kessler, T. M. et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: Systematic review and meta-analysis. Eur. Urol. 58, 865-874 (2010).
44. Levin, P. J., Wu, J. M., Siddiqui, N. Y. & Amundsen, C. L. Does obesity impact the success of an InterStim test phase for the treatment of refractory urge urinary incontinence in female patients? Female Pelvic Med. Reconstr. Surg. 18, 243-246 (2012).
45. Amundsen, C. L., Romero, A. A., Jamison, M. G. & Webster, G. D. Sacral neuromodulation for intractable urge incontinence: Are there factors associated with cure? Urology 66, 746-750 (2005).
46. Chermansky, C. J., Krlin, R. M., Holley, T. D., Woo, H. H. & Winters, J. C. Magnetic resonance imaging following InterStim®: An institutional experience with imaging safety and patient satisfaction. Neurourol. Urodyn. 30, 1486-1488 (2011).
47. Faucheron, J. L., Voirin, D. & Badic, B. Sacral nerve stimulation for fecal incontinence: Causes of surgical revision from a series of 87 consecutive patients operated on in a single institution. Dis. Colon Rectum 53, 1501-1507 (2010).
48. Elkelini, M. S. & Hassouna, M. M. Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator. Eur. Urol. 50, 311-316 (2006).
49. Medtronic. MRI Guidelines for InterStimTherapy neurostimulation systems [online], http://manuals.medtronic.com/wcm/groups/mdtcom-sg/@emanuals/@era/ @neuro/documents/documents/contrib-119885.pdf (2012).
50. Baxter, C. & Kim, J. H. Contrasting the percutaneous nerve evaluation versus staged implantation in sacral neuromodulation. Curr. Urol. Rep. 11, 310-314 (2010).
51. Vasavada, S. & Rackley, R. in Campbell-Walsh Urology 10th edn (eds Wein, A. J., Kavoussi, L. K., Novick, A. C., Partin, A. W. & Peters, C. A.) 2026-2046 (Elsevier Saunders, 2011).
52. Peters, K. M. Neuromodulation, staged intervention, and new instruments. Atlas Urol. Clinics North Am. 12, 275-291 (2004).
53. Peters, K. M., Killinger, K. A. & Boura, J. A. Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation? Neurourol. Urodyn. 30, 1489-1492 (2011).
54. Spinelli, M. et al. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: Description and first experience. J. Urol. 170, 1905-1907 (2003).
55. Siegel, S. W. et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56, 87-91 (2000).
56. Sherman, N. D., Jamison, M. G., Webster, G. D. & Amundsen, C. L. Sacral neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery. Am. J. Obstet. Gynecol. 193, 2083-2087 (2005).
57. Peters, K. M., Killinger, K. A., Boguslawski, B. M. & Boura, J. A. Chronic pudendal neuromodulation: Expanding available treatment options for refractory urologic symptoms. Neurourol. Urodyn. 29, 1267-1271 (2010).
58. Borawski, K. M., Foster, R. T., Webster, G. D. & Amundsen, C. L. Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women. Neurourol. Urodyn. 26, 14-18 (2007).
59. Carey, M., Fynes, M., Murray, C. & Maher, C. Sacral nerve root stimulation for lower urinary tract dysfunction: Overcoming the problem of lead migration. BJU Int. 87, 15-18 (2001).
60. Everaert, K. et al. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur. Urol. 45, 649-654 (2004).
61. Leong, R. K., De Wachter, S. G., Nieman, F. H., de Bie, R. A. & van Kerrebroeck, P. E. PNE versus 1st stage tined lead procedure: A direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol. Urodyn. 30, 1249-1252 (2011).
62. Sutherland, S. E. et al. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience. Neurourol. Urodyn. 26, 19-28 (2007).
63. Hassouna, M. M. et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: A multicenter study on efficacy and safety. J. Urol. 163, 1849-1854 (2000).
64. Latini, J. M., Alipour, M. & Kreder, K. J. Jr. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology 67, 550-553 (2006).
65. van Kerrebroeck, P. E. et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: Outcomes of a prospective, worldwide clinical study. J. Urol. 178, 2029-2034 (2007).
66. Bosch, J. L. & Groen, J. Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: Long-term results of a prospective longitudinal study. J. Urol. 163, 1219-1222 (2000).
67. Al-zahrani, A. A., Elzayat, E. A. & Gajewski, J. B. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J. Urol. 185, 981-986 (2011).
68. Groen, J., Blok, B. F. & Bosch, J. L. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J. Urol. 186, 954-959 (2011).
69. Hijaz, A. & Vasavada, S. Complications and troubleshooting of sacral neuromodulation therapy. Urol. Clin. North Am. 32, 65-69 (2005).
70. Blandon, R. E., Gebhart, J. B., Lightner, D. J. & Klingele, C. J. Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women. BJU Int. 101, 1119-1123 (2008).
71. White, W. M., Mobley, J. D. 3rd, Doggweiler, R., Dobmeyer-Dittrich, C. & Klein, F. A. Incidence and predictors of complications with sacral neuromodulation. Urology 73, 731-735 (2009).
72. Gaynor-Krupnick, D. M., Dwyer, N. T., Rittenmeyer, H. & Kreder, K. J. Evaluation and management of malfunctioning sacral neuromodulator. Urology 67, 246-249 (2006).
73. Huang, J. C., Deletis, V., Vodusek, D. B. & Abbott, R. Preservation of pudendal afferents in sacral rhizotomies. Neurosurgery 41, 411-415 (1997).
74. Spinelli, M. et al. A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: Description of the method and preliminary data. Neurourol. Urodyn. 24, 305-309 (2005).
75. Peters, K. M., Feber, K. M. & Bennett, R. C. Sacral versus pudendal nerve stimulation for voiding dysfunction: A prospective, single-blinded, randomized, crossover trial. Neurourol. Urodyn. 24, 643-647 (2005).
76. Peters, K. M. et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol. Urodyn. 32, 24-29 (2012).
77. Amarenco, G. et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J. Urol. 169, 2210-2215 (2003).
78. Peters, K. M. et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: Results from the SUmiT trial. J. Urol. 183, 1438-1443 (2010).
79. Wooldridge, L. S. Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency, and urge incontinence: Results from a community-based clinic. Urol. Nurs. 29, 177-185 (2009).
80. Zinkgraf, K., Quinn, A. O., Ketterhagen, D., Kreuziger, B. & Stevenson, K. Percutaneous tibial nerve stimulation for treatment of overactive bladder and urinary retention in an elderly population. Urol. Nurs. 29, 30-34 (2009).
81. Peters, K. M. et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: Results from the overactive bladder innovative therapy trial. J. Urol. 182, 1055-1061 (2009).
82. MacDiarmid, S. A. et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J. Urol. 183, 234-240 (2010).
83. Peters, K. M., Carrico, D. J., Wooldridge, L. S., Miller, C. J. & Macdiarmid, S. A. Percutaneous tibial nerve stimulation (PTNS) for the long-term treatment of overactive bladder: Three-year results of the STEP study. J. Urol. 189, 2194-2201 (2012).
84. Burton, C., Sajja, A. & Latthe, P. M. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. Neurourol. Urodyn. 31, 1206-1216 (2012).
85. Staskin, D. R., Peters, K. M., MacDiarmid, S., Shore, N. & de Groat, W. C. Percutaneous tibial nerve stimulation: A clinically and cost effective addition to the overactive bladder algorithm of care. Curr. Urol. Rep. 13, 327-334 (2012).